Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a Outperform recommendation.
Analyst Price Forecast Suggests 87.96% Upside
As of January 29, 2025, the average one-year price target for Vera Therapeutics is $68.68/share. The forecasts range from a low of $38.38 to a high of $112.35. The average price target represents an increase of 87.96% from its latest reported closing price of $36.54 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vera Therapeutics is 29MM. The projected annual non-GAAP EPS is -3.30.
What is the Fund Sentiment?
There are 379 funds or institutions reporting positions in Vera Therapeutics. This is an increase of 11 owner(s) or 2.99% in the last quarter. Average portfolio weight of all funds dedicated to VERA is 0.26%, an increase of 16.19%. Total shares owned by institutions increased in the last three months by 3.42% to 58,229K shares. 
The put/call ratio of VERA is 0.83, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 4,310K shares representing 6.81% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 3,939K shares representing 6.22% ownership of the company. In its prior filing, the firm reported owning 3,620K shares , representing an increase of 8.10%. The firm increased its portfolio allocation in VERA by 27.90% over the last quarter.
Sofinnova Investments holds 2,794K shares representing 4.41% ownership of the company. No change in the last quarter.
Commodore Capital holds 2,475K shares representing 3.91% ownership of the company. No change in the last quarter.
Eversept Partners holds 2,050K shares representing 3.24% ownership of the company. In its prior filing, the firm reported owning 2,043K shares , representing an increase of 0.34%. The firm increased its portfolio allocation in VERA by 22.62% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
